Drug Search Results
More Filters [+]

GSK-2816126

Alternative Names: gsk-2816126, gsk2816126, gsk 2816126, GSK126, GSK-126
Latest Update: 2024-05-30
Latest Update Note: PubMed Publication

Product Description

selective EZH2 inhibitor (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31471312/)

Mechanisms of Action: EZH2 Inhibitor,EED Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GSK-2816126

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Multiple Myeloma|Diffuse Large B-Cell Lymphoma|Lymphoma, Non-Hodgkin|Follicular Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT02082977

P1

Terminated

Follicular Lymphoma|Lymphoma, Non-Hodgkin|Diffuse Large B-Cell Lymphoma|Multiple Myeloma

2017-06-20

Recent News Events